Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

Forgot your password?

Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

I agree to TheMaven'sTerms andPolicy

Already have an account? Login here

JIM CRAMER INVESTING PERSONAL FINANCE RETIREMENT TECHNOLOGY MARKETS HOW-TO VIDEO FINANCIAL ADVISOR CENTER

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

Outlook Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

By GlobeNewswire
Dec 1, 2020 8:05 AM EST

Outlook Therapeutics Announces Creation Of Global Retina Advisory Council

By GlobeNewswire
Nov 19, 2020 8:05 AM EST

Outlook Therapeutics Secures $10 Million In Additional Working Capital

By GlobeNewswire
Nov 5, 2020 8:05 AM EST

Outlook Therapeutics Completes Patient Enrollment Of Open-Label Safety Study For ONS-5010/LYTENAVA™ (bevacizumab-vikg)

By GlobeNewswire
Nov 3, 2020 8:35 AM EST

Outlook Therapeutics To Present At The Virtual Investor KOL Roundtable

By GlobeNewswire
Oct 22, 2020 8:00 AM EDT

Outlook Therapeutics Announces Initiation Of Supplemental Open-Label Safety Study For ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

By GlobeNewswire
Oct 13, 2020 8:05 AM EDT

Outlook Therapeutics To Present At The Virtual BIO Investor Forum Digital

By GlobeNewswire
Oct 7, 2020 8:05 AM EDT

Outlook Therapeutics To Present At Two Upcoming Investor Conferences

By GlobeNewswire
Sep 8, 2020 8:05 AM EDT

Outlook Therapeutics Reports Topline Results And Positive Proof-of-Concept For ONS-5010 / LYTENAVA™ (bevacizumab-vikg) From NORSE 1

By GlobeNewswire
Aug 26, 2020 8:05 AM EDT

Outlook Therapeutics Announces Closing Of $1.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

By GlobeNewswire
Jul 17, 2020 8:05 AM EDT

Outlook Therapeutics Completes Patient Enrollment For NORSE 2 Study Of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

By GlobeNewswire
Jul 7, 2020 8:05 AM EDT

Outlook Therapeutics Announces Closing Of $10.2 Million Financing Priced At-The-Market Under Nasdaq Rules

By GlobeNewswire
Jun 25, 2020 8:05 AM EDT

Outlook Therapeutics Announces $11.2 Million Financings Priced At-The-Market Under Nasdaq Rules

By GlobeNewswire
Jun 23, 2020 8:00 AM EDT

Outlook Therapeutics Provides Clinical Update On ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

By GlobeNewswire
Jun 17, 2020 8:05 AM EDT

Outlook Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

By GlobeNewswire
Jun 11, 2020 8:05 AM EDT

Outlook Therapeutics To Present At The Virtual Investor Fireside Chat Series

By GlobeNewswire
Jun 9, 2020 8:05 AM EDT

Outlook Therapeutics Announces Closing Of $16.0 Million Private Placement

By GlobeNewswire
Jun 3, 2020 8:05 AM EDT

Outlook Therapeutics Announces $16.0 Million Private Placement To Advance The Development Of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

By GlobeNewswire
May 26, 2020 8:05 AM EDT

Outlook Therapeutics Bolsters Clinical And Commercial Expertise With Two Key Appointments To Board Of Directors

By GlobeNewswire
Apr 21, 2020 8:05 AM EDT

Outlook Therapeutics To Present At The April 2020 Virtual Investor Summit

By GlobeNewswire
Apr 15, 2020 8:35 AM EDT

Outlook Therapeutics Provides COVID-19 Impact Update On Ongoing Clinical Trials NORSE 1 And NORSE 2

By GlobeNewswire
Apr 14, 2020 8:05 AM EDT

Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name For ONS-5010, If Approved

By GlobeNewswire
Mar 5, 2020 8:00 AM EST

Outlook Therapeutics Announces Closing Of $10.2 Million Financings Priced At-The-Market

By GlobeNewswire
Feb 26, 2020 2:26 PM EST

Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market

By GlobeNewswire
Feb 24, 2020 8:00 AM EST

Terms Of Use
Privacy Policy
Advertise
Reprints
Customer Service
Data
Topic Archive
Subscriptions

© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.